Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared on X:
“One of the reasons why FDA rejected Ivonescimab approval claim is that 93 % events occur in China.
I have two questions.
- What is the cut off for events to occur in USA for US FDA to consider that data as good enough? Is there a number? 40 %, 50 %, 60 %?
- Guess this trial and tell me how US FDA will react to its results?
It has only 39 patients out of 602 (6.4%) from USA and in pre specified subset analysis they dont do well (see the graph on right) Hint – trial got maximum applause at ESMO 2026. The slide is from our upcoming OncoWisdom webinar on 20 th November to discuss ESMO 26 key data.
Do Register for OncoWisdom webinar if u have not done yet. 20 th November 7.30 pm IST.”

You can also read: FDA Withholds Ivonescimab Approval in EGFR-Mutant NSCLC: Why HARMONi’s PFS Benefit Was Not Enough
